<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705727</url>
  </required_header>
  <id_info>
    <org_study_id>ASTHMAFAST</org_study_id>
    <nct_id>NCT04705727</nct_id>
  </id_info>
  <brief_title>Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation</brief_title>
  <acronym>ASTHMAFAST</acronym>
  <official_title>Comparison of the Efficacy and Safety of Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Asthma Presenting at the Emergency Room for Moderate Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined use of inhaled corticosteroids and long-acting β-agonists (LABAs) as the controller&#xD;
      and the quick relief therapy termed single maintenance and reliever therapy (SMART) is a&#xD;
      potential therapeutic regimen for the management of persistent asthma. A recent systematic&#xD;
      review supports the combined use of inhaled corticosteroids and LABA as both the controller&#xD;
      and quick relief therapy (SMART) among patients aged 12 years. In Emergency room (ER),&#xD;
      Meta-analysis showed that using salbutamol (or albuterol) by meter doses inhaler (MDI) with a&#xD;
      valved holding chamber (VHC) in children with moderate-severe acute asthma exacerbation was&#xD;
      more effective, that is, fewer hospital admissions, more clinical improvement, and had fewer&#xD;
      adverse effects (tremor and tachycardia) than salbutamol by nebulizer. Therefore, several&#xD;
      international guidelines recommend the use of salbutamol by MDI rather than by nebulizer for&#xD;
      moderate-severe asthma exacerbations. In children older than 8 years old, dry-powder inhaler&#xD;
      (DPI), a device that delivers medication to the lungs in the form of a dry powder is&#xD;
      currently used for maintenance and reliever therapy rather than MDI. In this context, we aim&#xD;
      to assess the use of combined inhaled corticosteroids and long-acting β-agonists (LABAs) as a&#xD;
      quick relief therapy in children older than 8 years old presenting at the ER with moderate&#xD;
      asthma exacerbation. Acute asthma patients who had severe exacerbation were excluded from&#xD;
      this study (these patients receiving systematically continuous nebulized salbutamol and/or&#xD;
      intravenous salbutamol upon their arrival)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of success</measure>
    <time_frame>Up 30 minutes after the last administration</time_frame>
    <description>Percentage of success define by a pulmonary score &lt; 3 according to the number of administrations necessary to obtain this score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalized patients</measure>
    <time_frame>during the month following the asthma attack</time_frame>
    <description>Number of hospitalized patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in ER</measure>
    <time_frame>Up to discharge from the emergency room</time_frame>
    <description>Number of hours of stay in the ER</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score for the inhalation technique</measure>
    <time_frame>Immediately after each inhalation procedure</time_frame>
    <description>Score for the inhalation technique at each procedure from 0 to 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on the Asthma Control Questionnaire (ACT)</measure>
    <time_frame>1 week after randomisation</time_frame>
    <description>Score on the Asthma Control Questionnaire (ACT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on the Asthma Control Questionnaire (ACT)</measure>
    <time_frame>1 month after randomisation</time_frame>
    <description>Score on the Asthma Control Questionnaire (ACT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medical visit</measure>
    <time_frame>1 week and 1 month following the exacerbation</time_frame>
    <description>Number of medical visits at 1 week and 1 month following the exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>controlled asthma</measure>
    <time_frame>1 month following the exacerbation</time_frame>
    <description>Number of patients with a controlled asthma at 1 month following the exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 1 month following the exacerbation</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>1 month</time_frame>
    <description>FEV1 volume at 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total pulmonary capacity</measure>
    <time_frame>1 month</time_frame>
    <description>Total pulmonary capacity at 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital capacity (VC)</measure>
    <time_frame>1 month</time_frame>
    <description>Vital capacity volume at 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC ratio</measure>
    <time_frame>1 month</time_frame>
    <description>FEV1/FVC ratio at 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary score</measure>
    <time_frame>Within 5 minutes following each inhalation procedure</time_frame>
    <description>Pulmonary score at each procedure from 0 to 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>Within 5 minutes following each inhalation procedure</time_frame>
    <description>Oxygen saturation at each procedure expressed as a percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>Within 5 minutes following each inhalation procedure</time_frame>
    <description>Respiratory rate number of breathing cycles per minute</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Asthma in Children</condition>
  <arm_group>
    <arm_group_label>budesonide/formoterol Turbuhaler®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomization, patients in the experimental arm will receive budesonide/formoterol Turbuhaler® 100/6 μg, one inhalation every 5 minutes (Maximum 12 inhalations).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nebulisation of terbutaline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered. In case of an insufficient response, 3 additional doses will be administered for a maximum of 6 nebulisations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide Formoterol Drug Combination</intervention_name>
    <description>This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).</description>
    <arm_group_label>budesonide/formoterol Turbuhaler®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nebulisation of terbutaline</intervention_name>
    <description>Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.</description>
    <arm_group_label>nebulisation of terbutaline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children 8-17 years&#xD;
&#xD;
          -  Children consulting to the ER with moderate asthma exacerbation (defined by the&#xD;
             Pulmonary Score &gt; 3 and ≤7)&#xD;
&#xD;
          -  Score for the inhalation technique = 3&#xD;
&#xD;
          -  French social security affiliation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pneumonia&#xD;
&#xD;
          -  Pulmonary and/or cardiac congenital malformations&#xD;
&#xD;
          -  Chronic pulmonary disease other than asthma (bronchopulmonary dysplasia, cystic&#xD;
             fibrosis, or post infectious bronchiolitis obliterans)&#xD;
&#xD;
          -  Foreign body aspiration&#xD;
&#xD;
          -  Neurological alteration&#xD;
&#xD;
          -  Severe asthma exacerbation defined by Pulmonary Score &gt; 7&#xD;
&#xD;
          -  Cardiopulmonary failure imminent or mechanical ventilation indication&#xD;
&#xD;
          -  Thyrotoxicosis, pheochromocytoma, type 2 diabetes, untreated hypokalemia, obstructive&#xD;
             cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm&#xD;
             or other serious cardiovascular disorders such as ischemic heart disease,&#xD;
             tachyarrhythmias or severe heart failure.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding woman&#xD;
&#xD;
          -  Ongoing participation in RIPH1 Intervention Research&#xD;
&#xD;
          -  History of intolerance to terbutaline&#xD;
&#xD;
          -  Hypersensitivity to the active ingredient or any excipients of terbutaline&#xD;
&#xD;
          -  Hypersensitivity (allergy) to budesonide, formoterol or any component of the product&#xD;
             (lactose may contain milk proteins in small quantities)&#xD;
&#xD;
          -  Patient with an ongoing treatment of itraconazole, ritonavir or other potent CYP3A4&#xD;
             inhibitor, quinidine, disopyramide, procainamide, phenothiazines, antihistamines&#xD;
             (terfenadine), monoamine oxidase inhibitors (MAOIs), beta-blockers (including&#xD;
             eyedrops) and tricyclic antidepressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amelle Issa</last_name>
    <phone>+33157022632</phone>
    <email>amelle.issa@chicreteil.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Soussan Banini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent GAJDOS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien ROUGET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph EPAUD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de l'Est Francilien</name>
      <address>
        <city>Jossigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houmam EL JURDI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina CRAIU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François DUBOS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI Villeneuve-Saint-Georges</name>
      <address>
        <city>Villeneuve-Saint-Georges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara ARNOUK, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

